Clopidogrel Resistance and Embolism in Carotid Artery Stenting

Summary

The purpose of this study is to evaluate the efficacy and safety of the ticlopidine + ginko biloba compared to clopidogrel in clopidogrel resistant patients undergoing carotid artery stent placement. The investigators hypothesized that ticlopidine + ginko biloba is superior than clopidogrel in terms of post-stent ischemic lesions in these patients without serious complications.

Timeline

Start

2014-06

Primary completion

2017-12

Completion

2017-12

Outcome

Missed primary endpoint

paper The primary endpoint occurred in 12/22 patients (54.5%) in the clopidogrel group and 13/20 patients (65.0%) in the ticlopidine-ginkgo group (P = 0.610). PMID 30761076 ↗

paper however, compared to clopidogrel, it failed to improve surrogate and clinical endpoints in patients undergoing CAS. PMID 30761076 ↗

Publications

• Chung JW, Kim SJ, Hwang J, Lee MJ, Lee J, Lee KY, Park MS, Sung SM, Kim KH, Jeon P, Bang OY. Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting. Front Neurol. 2019 Jan 30;10:44. doi: 10.3389/fneur.2019.00044. eCollection 2019.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Clopidogrel	Small molecule	97.875 mg	—
Subject	Ginko Biloba	Unknown	80 mg	—
Subject	ticlopidine	Small molecule	250 mg	—

Indications